Activation of the epidermal growth factor receptor (EGFR) family is thought to play an important role in mammary tumorigenesis and metastasis. The potent transforming activity of the EGFR family is due to their ability to heterodimerize with each other in response to a number of mitogenic ligands. The formation of EGFR and ErbB-2 heterodimers has been recently implicated as an important factor in the induction of sporadic human breast cancers. To directly assess whether the catalytic activity of EGFR is required for ErbB-2 induction of mammary tumors, we have interbred transgenic mice expressing ErbB-2 oncogene under the transcriptional control of the mouse mammary tumor virus (MMTV) promoter/enhancer to a naturally occurring mouse mutant carrying a catalytically impaired EGFR (waved-2 mice). Although the female transgenic mice possessing mutant EGFR developed mammary tumors, the tumors occurred only after a delayed latency period, and were fewer in number. The impaired tumor phenotype was further correlated with debilitated phosphorylation of the Gab1 multisubstrate adapter. These observations provide evidence that efficient ErbB-2-induced mammary tumor progression requires EGFR-dependent activation of Gab1. Oncogene (2003) 22, 9151-9155.
Introduction
Elevated expression of members of the epidermal growth factor receptor (EGFR) family that comprises the EGFR (HER), ErbB-2 (Neu, HER2), ErbB-3 (HER3) and ErbB-4 have frequently been observed in sporadic breast cancers (Slamon et al., 1987 (Slamon et al., , 1989 Kraus et al., 1989; Plowman et al., 1993; Sliwkowski et al., 1994) . Amplification and overexpression of erbB-2/neu proto-oncogene is observed in 20-30% human breast cancer, and is inversely correlated with the survival of the patient (Andrulis et al., 1998; Slamon et al., 1989) . Direct evidence supporting a role for the various EGFR family members and their various ligands in mammary tumorigenesis derives from observations made with transgenic mice. Mammary epithelial expression of EGFR, ErbB-2 or the EGFR ligand TGFa in transgenic mice resulted in the frequent induction of mammary adenocarcinomas (Muller et al., 1988; Matsui et al., 1990; Sandgren et al., 1990; Guy et al., 1996) . Genetic and biochemical analyses of these various transgenic mouse models have also revealed a potential role for other members of the EGFR family. For example, coexpression of the EGFR ligand TGFa with the ErbB-2 proto-oncogene resulted in dramatic acceleration of tumor progression that was further correlated with the tyrosine phosphorylation of EGFR and ErbB-2 . Conversely, inhibition of EGFR function by the administration of EGFR-specific inhibitors can dramatically impair mammary tumor formation in transgenic animals coexpressing TGFa and ErbB-2 in mammary epithelium (Lenferink et al., 2000) .
The ability of EGFR and ErbB-2 to collaborate with each other is thought to be due to their ability to form specific heterodimers (Stern and Kamps, 1988; Goldman et al., 1990; Karunagaran et al., 1996) . To test the in vivo importance of EGFR function in ErbB-2 tumor progression directly, we have interbred a naturally occurring mouse mutant that carries a catalytic impaired EGFR (waved-2) (Luetteke et al., 1994; Fowler et al., 1995) with separate transgenic strains carrying an erbB-2 oncogene under the transcriptional control of the mouse mammary tumor virus promoter (Siegel et al., 1999) . The results revealed that female mice homozygous for the mutant EGFR developed fewer mammary tumors that arose only after a long latency period. The delay in tumor onset was further correlated with a decrease in the tyrosine phosphorylation of the Gab1 adapter protein.
These observations suggest that the catalytic activity of EGFR is involved in modulating ErbB-2-mediated tumor progression through Gab-1 adapter protein.
Results and discussion

Expression of a kinase-impaired EGFR delays ErbB-2-mediated tumorigenesis
To investigate the role of the EGFR in ErbB-2-mediated tumorigenesis, we have interbred separate strains of mice that express an activated ErbB-2 oncogene under the transcriptional control of the MMTV/promoter enhancer (NDL 1-2) (Siegel et al., 1999) with a naturally occurring mouse mutant that has impaired EGFR function (waved-2). Waved-2 mice have a mutation in their endogenous EGFR kinase domain that greatly decreases their ability to both autophosphorylate and phosphorylate exogenous substrates (Luetteke et al., 1994; Fowler et al., 1995) . Since genetic background can alter tumor latency in MMTV/erbB-2 strains (Rowse et al., 1998) , the waved-2 strains were introgressed into an FVB background that is known to be permissive for ErbB-2-induced mammary tumor progression (Siegel et al., 1999) . Cohorts of female mice carrying the MMTV-activated neu oncogene on a waved-2 homozygous, waved-2 heterozygous, waved-2 homozygous MMTV/NDL1-2, waved-2 heterozygous MMTV/ NDL1-2 and wild-type EGFR were generated and monitored for mammary tumor formation. The results revealed that onset of mammary tumor formation was significantly impaired in animals carrying both copies of the mutant EGFR allele with average age of tumor formation at 281 days (n ¼ 27) compared with the 180 days (T 50 ¼ 180; n ¼ 28) observed with female mice carrying both wild-type EGFR alleles. Using a twotailed t-test, the difference in the average age of tumor onset between MMTV/NDL1-2 mice and waved-2 homozygous MMTV/NDL1-2 mice is statistically significant (Po0.05) (Figure 1a) . Interestingly, mice carrying a single-mutant Waved-2 allele showed an intermediate tumor onset, suggesting that a waved-2 mutant can act in a dominant-negative fashion to interfere with mammary tumor progression.
In addition to delaying tumor formation, we have observed that animals harboring defective EGFR kinase also have significant decrease in the number of visible mammary tumors in the mouse 2 months after initial tumor palpation (Figure 1b) . In all, 77% of the waved-2 homozygous MMTV/NDL1-2 mice (n ¼ 13) and 80% of the waved-2 heterozygous MMTV/NDL1-2 mice (n ¼ 15) had 0-5 tumors. In contrast, 44% of the MMTV/NDL1-2 mice (n ¼ 18) had 0-5 tumors, whereas 66% possessed six or more tumors. No significant differences in the metastatic rate were observed between the different cohorts of mice. In addition, histological examination of the tumors that arose in the various different genetic combinations revealed an identical comedocarcionoma phenotype (data not shown). Taken together, these observations suggest that the catalytic activity of EGFR is required to promote efficient ErbB-2 tumor progression.
The EGFR is phosphorylated, and forms heterodimers with ErbB-2 in waved-2 homozygous MMTV/NDL1-2, waved-2 heterozygous MMTV/NDL1-2 and MMTV/ NDL1-2 mice To elucidate the molecular basis for the observed delay in tumorigenesis in the homozygous waved-2 mice, we examined the activation status of the various members of the EGFR family that are known to be expressed in these tumors. Previous studies had demonstrated that these mammary tumors expressed EGFR, ErbB-2 and ErbB-3 (Siegel et al., 1999) . To accomplish this, we first immunoprecipitated tumor lysates with phosphotyrosine-specific antisera, followed by immunoblot analyses with the antibodies directed against the various EGFR family members. Examination of the phosphorylation status of EGFR revealed that EGFR is tyrosine phosphorylated in ErbB-2-induced tumors derived from mice homozygous for the Waved-2 mutation (Figure 2a , lanes 6-9) albeit at lower levels than tumors bearing wild-type EGFR allele (Figure 2a , compare lanes 2-8 to 6-9). To explore whether Waved-2 mutation could potentially interfere with the transphosphorylation of ErbB-2 or ErbB-3, we examined the phosphorylation status of ErbB-2 and ErbB-3 in the mammary tumors from the various Waved-2. The results showed that ErbB-2 and ErbB-3 are also phosphorylated at equal levels in all tumor genotypes (Figure 2b, c) . These data argue that EGFR Epidermal growth factor receptor-dependent activation A Gillgrass et al kinase activity is not required for activation of any of these EGFR family members. One potential explanation for the presence of tyrosine-phosphorylated EGFR in tumors derived from the waved-2 homozygous mice is that the EGFR is transphosphorylated by ErbB-2 through the formation of specific ErbB-2/EGFR heterodimers. To explore this possibility, we performed reciprocal coimmunoprecipitations with EGFR-or ErbB-2-specific antisera. Immunoblot analyses of EGFR or ErbB-2 immunoprecipitates revealed the presence of ErbB-2 or EGFR, respectively, in either wild-type or mutant Waved-2 tumors (Figure 3a compare lanes 2-5 with 6-7). No differences in the levels of EGFR/ErbB-2 complexes or the levels of EGFR or ErbB-2 were noted in these tumor lysates (Figure 3 ). These observations suggest that the observed tyrosine phosphorylation of EGFR in the waved-2 mutant strains is likely due to the transphosphorylation of mutant EGFR by ErbB-2.
Gab1 signaling is impaired in waved-2 homozygous MMTV/NDL1-2 tumor
Another potential explanation for the observed delay in tumor formation in the waved-2 strains is that kinase activity of EGFR is required for the activation of key downstream substrates of the EGFR. To explore this possibility, we examined the phosphorylation status of a number of well-characterized EGFR substrates. Among the EGFR substrates that have been examined, we noted than the multisubstrate adapter known as Gab1 appeared to be differentially tyrosine phosphorylated in the waved-2 strains (Figure 4a ). In particular, we noted that tumors derived from waved-2 animals exhibited significantly lower levels of tyrosine-phosphorylated Gab1 compared to the tumors arising in control animals ( Figure 4a , compare lanes 2-7 to 8-14). The observed differences in tyrosine-phosphorylated Gab1 were not due to differences in the levels of Gab1 since both sets of samples expressed comparable levels of Gab1 (Figure 4a) . Another important signal output of Figure 2 EGFR, Neu and ErbB3 are activated in waved-2 homozygous MMTV/NDL1-2, waved-2 heterozygous MMTV/ NDL1-2 and MMTV/NDL1-2 mice. (a) EGFR (top) and phosphotyrosine (bottom) were immunoprecipitated from 1 mg of total mammary tumor protein lysates, and both were blotted with EGFR. The activation status of (b) Neu and (c) ErbB3 was examined using the same method. Protein lysate from an FVB mammary gland was included as a negative control Grb-2 blots were included to control for equivalent amounts of protein loading. In all panels, protein lysate from an FVB mammary gland was included as a negative control Epidermal growth factor receptor-dependent activation A Gillgrass et al EGFR/ErbB-2 heterodimers is the MAP kinase (MAPK) family. To assess whether phosphorylation status of MAPK was affected in the ErbB-2-induced tumors derived from either wild-type or waved-2 tumors, we subjected the tumor lysates to immunoblot analysis with MAPK phosphospecific antibodies (Figure 4b ). Although the state of MAPK was somewhat variable between the tumor samples, we did not observe consistent differences in MAPK phosphosphorylation (Figure 4b ).
To ensure that the observed differences in Gab1 tyrosine phosphorylation were not due to differences in the ability of Gab1 to interact with the waved-2 EGFR, we assessed whether Gab1 could be detected in EGFR immunoprecipitates from either waved-2 or wild-type-derived tumors. The results showed that equal levels of Gab1 were detected in either mutant of wild-type EGFR receptors ( Figure 5 ). Taken together, these results suggest that the low levels of Gab1 phosphorylation are not due to the inability of Gab1 to associate with the mutant EGFR, and suggest that the delay in tumor induction may be due to inability of the waved-2 mutant to activate the Gab-1-signaling pathway.
Mammary tumor induction by the EGFR family is thought to involve the formation of different EGFR heterodimer combinations . In transgenic mice expressing activated erbB-2 oncogene in the mammary epithelium, we have previously demonstrated that the EGFR, c-erbB-2 and c-erbB-3 are the major EGFR family members that are expressed (Siegel et al., 1999) . Previous studies have demonstrated that coactivation and erbB-2 resulted in a dramatic acceleration in the onset of mammary tumors . Consistent with these observations, we have found that impairment of the catalytic activity of EGFR through introduction of naturally occurring waved-2 mutation can result in a dramatic impairment of ErbB-2-induced mammary tumors.
Although transphosphorylation of this catalytically impaired EGFR was not affected, we noted that the multisubstrate adapter protein Gab1 was not efficiently tyrosine phosphorylated in the waved-2 genetic background, suggesting that Gab1 was a specific substrate of the EGFR. One possible explanation for the increased tumor latency, is that, due to the inefficient phosphorylation of Gab1, Gab-1 cell survival or proliferative pathways are compromised resulting in premature apoptotic cell death of arising tumor cells. In this regard, it has previously been demonstrated that introduction of the Waved-2 mutation can dramatically interfere with skin carcinogenesis in transgenic mice expressing an activated SOS oncogene (Sibilia et al., 2000) . These investigators further demonstrated that catalytic activity of EGFR was required for the generation critical anti-apoptotic signal (Sibilia et al., 2000) . Although inactivation of EGFR catalytic activity resulted in a delay in mammary tumor formation, female animals bearing the Waved-2 EGFR eventually developed mammary tumors. One possible explanation for these observations is that other members of the EGFR family such as ErbB-3 can independently recruit and activate the PI-3K-signaling pathway and thus functionally substitute for the lack of EGFR/Gab dependent activation of PI-3K. Future studies directed towards the concerted targeting of EGFR and ErbB-3 should allow this hypothesis to be tested. . In all panels, protein lysates from an FVB mammary gland were included as a negative control Figure 5 Gab1 is able to associate with EGFR in waved-2 homozygous MMTV/NDL1-2 and MMTV/NDL1-2 mice. (a) Total mammary tumor protein lysate (1 mg) was immunoprecipitated with EGFR and blotted with Gab1. (b) The same lysates (20 mg) in (a) were blotted with EGFR and Gab1. Grb-2 was also blotted to control for equivalent amounts of protein loading Epidermal growth factor receptor-dependent activation A Gillgrass et al
Materials and methods
Generation and identification of mouse strains
MMTV/NDL1-2 mice were generated by Siegel et al. (1999) . The initial description of the waved-2 natural mutant can be found in Luetteke et al. (1994) and Fowler et al. (1995) . C57/ BL6 waved-2 mice were ordered from Jackson Laboratories and backcrossed into an FVB background for eight generations, before being crossed with the MMTV/NDL1-2 mice. Both strains were identified by PCR genotyping.
Immunoprecipitation and immunoblotting
Tissue samples were prepared and lysed in TNE lysis buffer, as described in detail by Siegel et al. (1999) . In immunoprecipitations, the desired amount of protein (described in figure legends), 20-40 ml of protein G sepharose beads (Pharmacia) and 1-4 mg of the appropriate antibody were combined and brought to a volume of 500 ml with TNE lysis buffer. The reaction was incubated at 41C on a rotator for 3 h. Beads were then washed five times in TNE lysis buffer. After the final rinse, the beads were resuspended in SDS loading buffer (62.3 mm Tris-HCl (pH 6.8), 2% SDS, 5% glycerol, 0.8 m 2-mercaptoethanol, 0.25% bromophenol blue). In some cases, if two assays were being used on the same lysates, the solution was separated into two equal volumes before resuspension in SDS loading buffer. The beads in the SDS loading buffer were boiled for 5 min and spun down. The supernatant was then removed for further analysis. Western blot protocols have been described elsewhere (Muthuswamy et al., 1994) with several exceptions; proteins were resolved on SDS-10% polyacrylamide gels, blocking was performed for 1 h, primary antibodies were incubated overnight and the secondary dilution was 1 : 2500.
Antibodies
EGFR was detected in immunoprecipitations and immunoblotting with a mouse monoclonal antibody from Transduction Laboratories (Cat#E12020). ErbB-2 was immunoprecipitated with Ab-4 (Cat#OP16) and blotted with Ab-3 (Cat#OP15) (Oncogene Science). For ErbB3 immunoprecipitation and blotting, C-17 antibody from Santa Cruz was utilized (Cat#285). PY20 (Transduction LaboratoriesCat#P11120) was used to immunoprecipitate and blot for phosphotyrosine. Grb2 was detected with C-23 (Santa-Cruz, Cat#sc255). Gab1 was immunoprecipitated and blotted with an anti-Gab1 (C-Terminus) antibody from Upstate Biotechnology (Cat#06-579. Antibodies to p42/44 MAPK (Cat#9101) and phosphorylated p42/44 MAPK were all from New England Biolabs.
